Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.0M | $50.7M | $17.2M | $15.1M | $17.3M | $827.0K | $51.6M | $6.1M |
| Cost of revenue | $89.0K | $549.0K | $559.0K | $584.0K | $554.0K | $422.0K | $1.7M | $1.7M |
| Gross profit | $72.9M | $50.1M | $16.7M | $14.5M | $16.7M | $405.0K | $49.9M | $4.4M |
| Gross margin | 99.9% | 98.9% | 96.8% | 96.1% | 96.8% | 49.0% | 96.7% | 71.9% |
| R&D | $58.6M | $87.7M | $89.4M | $75.8M | $17.0M | $36.1M | $97.0M | $141.2M |
| Operating income | −$13.6M | −$71.9M | −$106.5M | −$101.4M | −$20.0M | −$56.2M | −$99.0M | −$185.1M |
| EBITDA | −$38.1M | −$71.9M | −$106.5M | −$101.4M | −$19.4M | −$54.0M | −$57.2M | −$164.2M |
| Net income | −$39.2M | −$91.1M | −$91.9M | −$95.4M | −$46.9M | −$81.6M | −$101.3M | −$184.6M |
| Net margin | -53.7% | -179.8% | -532.9% | -632.0% | -271.5% | -9869.6% | -196.2% | -3012.6% |
| EPS (diluted) | -0.00 | -0.00 | -0.00 | -0.00 | -1.11 | -6.20 | -2.22 | -2.87 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds KDNY.
No tracked institution reports a position in KDNY as of their last filing.
| Execution date | Ratio |
|---|---|
| 2020-10-02 | 1-for-5reverse |
No one on the platform has traded KDNY yet.
| $1.8B |
| — |
| LBPHLongboard Pharmaceuticals, Inc. | $59.98 | — | $2.3B | — |
| MORMorphoSys AG | $18.96 | +2.43% | $2.9B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$NVS Not a poster on this tab but wanted to share that today, received $2 value rights from Novartis' acquisition of Chinook Therapeutics ($KDNY) arising from the approval of Atrasentan. There are $2 more in milestones to go as commercialiation develops.
View on StockTwits ↗…good example of why hiring / firing decisions can be noise in predicting outcomes for an outside investor. Because $PLRX Pliant was on a major hiring push just a month ago. Including hiring the CTO Dr Imbert after a very successful sale of $KDNY Chinook to NVS .
View on StockTwits ↗~ In May 2023, Muddy Waters accused # Chinook and AbbVie of manipulating trial results for lead product candidate. ~ $KDNY fell 7%, losing $100M+ shareholder value. ~ Investors may suspect $KDNY of unlawful biz practices, which led to their losses => https://11thestate.com/cases/chinook-investor-case
View on StockTwits ↗$KDNY how is the chart here the same every day? This is a scam.
View on StockTwits ↗$KDNY anyone know what happens to my call exp 8.18? How will they expire? Do I get paid? I wrote to chinook and they haven't responded.
View on StockTwits ↗$KDNY Had some short $40 $KDNY calls called away right before the deal closed. So as of today, I am short about 1500 shares at ~$40.73 (strike plus premium). I know that my account will be debited $40 per share because of the $40 per cash offer. But what happens to the CVRs? Will a CVR security be issued? Will it trade on an exchange? I will be short that security and will be looking to close out my position. How do thinks proceed from here?
View on StockTwits ↗@BeaconABB Short term damage from capital raise to complete Ph3 activities. But they know owning a big winner for long term, with future partnerships or even potential buyout. I own $KDNY and got 6x gain from recent buyout by $NVS. Just my opinion and not financial advice. Do your own DD and place your bet GL
View on StockTwits ↗$CMCSA, $KDNY and $ANF are making a new 52 week high. https://www.chartmill.com/stock/stock-screener?f=p_pg10,v1_50b500,s_nh,exch_us&v=3&utm_source=New_52_week_high_today&utm_medium=stocktwits&utm_campaign=screen
View on StockTwits ↗$KDNY trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $40.32 Vol: 4.92M.
View on StockTwits ↗@OB1OB2 I'm a pro and don't often lose! LOL Still have plenty of gain from $KDNY being bought out. Bring on this Thursday 8/10 corporate update, then I shall hit another homerun this year with $VTGN? Got to love the science that can help 25M Americans? 🚀🚀
View on StockTwits ↗Chinook Therapeutics downgraded by Wedbush to neutral. $42.00 PT. www.marketbeat.com/stocks/NASDAQ/KDNY/price-target/ $KDNY
View on StockTwits ↗$VTGN My first home run was with $KDNY after buyout offer by $NVS this year, and now just picked up 5,000 shares of VistaGen avg ~$13 today. Very positive topline Ph3 results! Target $30+ this week and better days ahead! GLTA
View on StockTwits ↗$AUPH Jefferies:" $AUPH CC Thursday 8.30am; 2Q est of $39M (vs $37.4M cons) for Lupkinis; reasonable acquisition value could be ~2.5-3.5X, referencing historical avg, recent $KDNY acquisition, and assuming some discount for IP risk. We est $AUPH peak sales $600M WW in 2027."
View on StockTwits ↗$KDNY was analyzed by 17 analysts. The buy consensus is at 74%. So analysts seem to be mildly confident about $KDNY. https://www.chartmill.com/stock/quote/KDNY/analyst-ratings?utm_source=stocktwits&utm_medium=ANALYST&utm_content=KDNY&utm_campaign=social_tracking
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.